Blog

The genetic variances were computed via GCTA v1.24[22], which is a tool for estimating the proportion of phenotypic variance that is explained by genome-wide SNPs for complex traits[23]. their association with the 10 metabolic traits in 2 Korean populations (Ansung and Ansan). The proportion of phenotypic variance explained by eQTL and non-eQTL SNPs showed that eQTL SNPs were more likely to be associated with the metabolic traits genetically compared with non-eQTL SNPs. Finally, via a meta-analysis of the two Korean populations, we identified 14 eQTL SNPs that were significantly associated with metabolic traits. These results suggest that our approach can be expanded to other genome-wide association studies. == Introduction == Recently, large-scale genome-wide association studies (GWAS) that comprised several thousands of samples have reported many novel findings in various diseases and disease-related phenotypes[1]. These findings have been enlightening the path to the identification of disease mechanisms and biomarkers. Among the human phenotypes, Dabrafenib (GSK2118436A) metabolic traits are frequently studied in different populations[2]. In the Korean population, common metabolic traits, such as glucose, cholesterol, and bilirubin levels, have been studied via conventional GWAS[3],[4]. However, little was explained by heritability[3]. This phenomenon, which is termed the missing heritability problem, is hard to resolve by conventional GWAS. It was suggested that the missing heritability might come from the stringent multiple testing correction of GWAS analyses[5]. This multiple screening correction is necessary to exclude false-positive loci, but simultaneously may discard many true-positive loci[6]. In additional studies, it was demonstrated that reducing the number of checks is definitely advantageous for GWAS. In that research, the categorization of the genome-wide SNPs into practical categories provided the opportunity to reduce multiple testing and to determine practical variants[7],[8]. In addition to the missing heritability, it should be considered that most of the significant single-nucleotide polymorphisms (SNPs) used in these GWAS lay in intergenic and intron areas and had little association with changes in the protein-coding sequences of genes[1]. Therefore, these SNPs likely regulate gene activity in the transcript level directly, or cooperate with additional DNA variations that mediate this type of rules. Based on these facts, manifestation quantitative loci (eQTL) are becoming actively analyzed for elucidating the relationship between changes in genotype and manifestation dynamics, that may promote the understanding of the results of GWAS[9][15]. eQTL info provides insights into Dabrafenib (GSK2118436A) the rules of transcription and aids in the interpretation of genome-wide association studies[9]. In cases in which the allelic changes of a SNP are significantly correlated with the manifestation of a gene, the SNP is definitely defined as an eQTL-SNP. Using this information, experts try to determine trait-associated SNPs that SMARCB1 would be normally hard to find. For example, Fransen and colleagues reported a GWAS for Crohns disease using eQTL-SNP info. Those authors selected eQTL SNPs among the GWAS results for Crohns disease, and performed follow-up replication studies[6]. They showed the eQTL-based preselection for follow-up studies was a useful approach for identifying risk loci from your results of a moderately sized GWAS. Here, we reanalyzed genome-wide associations between metabolic characteristics and SNPs using eQTL info. The main goal of this study was to explore metabolic trait-associated variants using an eQTL-based filtering strategy. The major eQTL SNPs used in Dabrafenib (GSK2118436A) this study were from the RegulomeDB, and the additional eQTL SNPs were obtained from recent reports of liver cells[13]and from lymphoblastoid cell lines[14]. We collected the genotypes of the eQTL SNPs from your Korean Association Source (KARE)[3],[16]and examined their association with 10 metabolic characteristics in two self-employed Korean cohorts (Ansan and Ansung). == Materials and Methods == == Study subjects == The study subjects comprised two population-based cohorts, Ansung and Ansan, which have been examined as part of the Korean Genome and Epidemiology Study (KoGES). The phenotype of the cohort has been described[17]. Briefly, the subjects came from Ansung and Ansan in KyungGi-Do province, near Seoul, Korea. Written educated consent was from all participants, and this research Dabrafenib (GSK2118436A) project was authorized by the institutional review table of KNIH. A total of 10,038 individuals were recruited for the cohorts, and 8,842 individuals of the KoGES were analyzed from the Korean Association Source (KARE) consortium to understand their genome-wide association with the surveyed or Dabrafenib (GSK2118436A) measured phenotypes[16]. Subjects with genotype accuracies below 98% and.